Japan could become one of the first countries in the world to end the HIV epidemic, says the president of Gilead Sciences Japan, Kennet Brysting. The idea for now could seem a little too ambitious, but it is not entirely unrealistic, given that the availability of medicines that can prevent transmission of HIV. Drugs are not the cure, but control over the spread of virus to the point where the disease is no longer a major public health threat.

What Is The Role Of Preventative HIV Medicines?

Gilead's have two key drugs, Truvada and lenacapavir. These two are playing a crucial role in prevention. Truvada is taken as a daily pill, while lenacapavir requires two injections per year. It can make the virus undetectable in infected individuals and prevent transmission to those who are not infected yet. In trials, lenacapavir showed 100% efficacy in preventing HIV infections. This is why it is describe as "almost a vaccine".

In 2024, Japan also approved Truvada for HIV prevention, but the country has yet to approve lenacapavir for the same. Until now, people in Japan had been importing generic versions of Truvada or purchasing it from clinics that source it from overseas.

HIV In Japan

Up until now, Japan reported around 25,000 HIV infections, whereas 669 new cases were reported in 2023. For seven consecutive years, the number of new infections remained under 1,000. The downward trend thus shows that the virus has been controlled, however, getting to zero new infections remains the ultimate goal.

Brysting too acknowledged that simply having effective drug is not enough. What is important is to have a proper implementation, access and healthcare support to make sure that these treatments are widely available and effective.

What Are The Challenges In Implementation?

The biggest challenges is testing rates. There is a need to increase testing rates. At this very moment, around 86% people infective with Japan have been tested, but the goal is to increase it up to 95%, with an ideal goal of 100%. Without widespread testing, many infected people may not even know that they are infected and it could transmit the virus.

Another measure issue is the cost of preventative medication. While Japan's health insurance covers treatments for diseases, it does not cover preventative drugs. Those who purchase Truvada for prevention, pay around $470 per month. Some clinics in Tokyo offer generic alternatives too, which is cheaper, but they are not ideal.

Better Healthcare Support

Brysting expressed concern that individuals importing medications might not be consulting doctors regularly, which is essential for monitoring HIV status and overall health. Truvada users need to be tested for HIV initially and every three months, along with screenings for other infections and kidney function checks. Without proper medical supervision, there is a risk of misuse and inadequate protection.

Gilead is in discussions with Japanese authorities to improve access and insurance coverage for Truvada, and progress is being made. Japan has shown efficiency in approving critical medicines, as seen during the COVID-19 pandemic when Gilead’s remdesivir was approved in just three days.

What Is The Way Ahead?

Gilead at this moment is not only focused on HIV and hepatitis C, but also expanding into oncology with innovative treatments like CAR-T cell therapy, which strengthens a patient's immune system to fight cancer.

However, Japan’s strict approval processes can slow down drug availability. Phase 3 clinical trials often need to be conducted within the country, and Japan tends to approve medicines much later than other regions. For instance, Truvada was approved for prevention in Japan 12 years after the U.S. and nearly 20 years after its approval for treatment. inancial factors also play a role. The Japanese government adjusts drug prices annually, often reducing them, which can make long-term investment challenging for pharmaceutical companies.

COVID-19 infections have resurfaced in India, with Andhra Pradesh reporting two deaths and several active cases, prompting health authorities to step up surveillance and preparedness measures.

A 52-year-old man from Kadapa's Rajampet area, who tested positive for COVID-19 after developing fever and cough, died while undergoing treatment at Christian Medical College (CMC), Vellore.

In another case, a 43-year-old man from Kadapa, who was admitted to the Government General Hospital with health complications, tested positive and later died while receiving treatment in the COVID-19 Intensive Care Unit.

A 25-year-old medical student from Kadapa Medical College has also tested positive for the virus and is currently undergoing treatment through home isolation. Several more cases have also been reported.

What Variant Is Causing The Reported Cases?

Doctors say they have seen a rise in COVID-19 cases over the past few weeks.

Dr. Lancelot Pinto, Consultant Pulmonologist and Epidemiologist at the PD Hinduja Hospital, Mumbai, told HealthandMe that SARS-CoV-2 has frequently been detected in patients presenting with viral respiratory infections.

"So when we send throat swabs in the context of a viral respiratory infection, we have detected SARS-CoV-2 as the causative organism often. It doesn't seem that this is a more virulent strain based on our experience so far. But in those who are immunocompromised, who are vulnerable because of their health risks, it can cause severe disease."

While the exact variant behind these cases has not yet been confirmed and samples have been sent for genome sequencing, experts say the virus currently circulating in India is largely made up of Omicron sub-lineages.

"The virus currently circulating in India is largely made up of Omicron sub-lineages, which generally cause milder illness than earlier variants, though they remain highly transmissible," Dr. Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, told HealthandMe.

Why Are We Still Seeing Severe COVID Despite Herd Immunity?

According to Dr. Pinto, viruses are capable of triggering what is known as an inflammatory cascade—a strong immune response that can sometimes contribute to severe illness.

"This cascade is such that there's a strong immune response to the virus that can sometimes be detrimental to humans, causing severe disease. We also know that any viral infection, however innocuous it may seem, has the potential of increasing your cardiovascular risk."

He explained that viral infections can also increase cardiovascular risk, meaning people already at risk of heart-related complications may experience poorer outcomes.

"And therefore, those who are at an increased risk of cardiovascular events could suffer from poor outcomes in the context of any viral infections."

Another concern, he said, is the limited availability of antiviral medicines.

"What has been concerning, though, is the difficulty of procuring antivirals at present. So drugs such as remdesivir and paxlovid are not easily available. And therefore, we are not able to offer it to vulnerable and high-risk individuals. And I hope this gets fixed in the near future."

Who Is At High Risk?

Although the circulating Omicron sub-lineages generally cause milder illness, they can still lead to severe disease in vulnerable individuals.

Those most at risk include:

• Senior citizens
• People with diabetes, heart disease, chronic lung disease, or chronic kidney disease
• Individuals with weakened immunity
• Pregnant women
• People who are unvaccinated or have not received recommended booster doses.

How To Reduce The Risk?

Despite the lower overall severity of the current variants, health experts say vigilance remains important. To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell.

Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice.

"If you are a high-risk individual and suffer from diseases such as diabetes, high blood pressure, chronic kidney disease, chronic liver disease, or respiratory disease such as COPD, this is the time to be a little cautious about exposing yourself to those who are ill, trying and avoiding crowds, trying and avoiding places where there's a conglomeration of individuals together and easy to pick up viruses. Mask up with a high-efficiency mask if it's feasible, especially if you are exposed to such kind of situations," Dr Pinto said.

For people without these underlying conditions, he said the virus appears to behave much like other seasonal respiratory viruses.

"For the average person who does not have a high risk in terms of these comorbidities, it does appear that this virus behaves just like any other seasonal influenza virus or any other seasonal virus."

Europe's record-breaking June heatwave led to an estimated 10,000 excess deaths across 27 countries, with older adults accounting for the overwhelming majority of fatalities, according to official data.

Data published by EuroMOMO—a mortality monitoring network supported by the European Centre for Disease Prevention and Control (ECDC) and the World Health Organization (WHO)—showed around 10,000 excess deaths during the week of June 22-28, when extreme heat peaked across France, Spain, Britain and several other European countries.

More than 9,000 of these deaths were among people aged 65 years and older.

"To have this kind of excess at this time of year is unusual. It's really high," Lasse Vestergaard, Chief Physician at Denmark's Statens Serum Institut, which hosts EuroMOMO, was quoted as saying to Reuters news agency.

"It is difficult to explain this high excess mortality by anything but the extreme heat," he added.

The figures are based on all-cause mortality, meaning they include deaths from all causes rather than only those officially classified as heat-related.

Scientists have also said the late-June heatwave would have been "virtually impossible" without human-caused climate change, which is making extreme heat events more frequent and intense.

England And Wales Saw 2,700 Heat-Related Deaths

A separate analysis by researchers from the London School of Hygiene & Tropical Medicine (LSHTM), Imperial College London, and the Met Office estimated more than 2,700 excess heat-related deaths during the May and June 2026 heatwaves in England and Wales.

Researchers estimated:

• Around 550 heat-related deaths occurred during the May 21-29 heatwave.
• Around 2,200 heat-related deaths occurred during the June 18-28 heatwave.

The study found that around 42% of the total heat-related deaths across both heatwaves were attributable to human-caused climate change.

Climate Change Intensified The Heat

According to the report, climate change increased daytime maximum temperatures across England and Wales by 3°C to 4°C.

The analysis estimated that climate change was responsible for:

• About 59% of heat-related deaths occurred during the May heatwave.
• Around 38% of heat-related deaths occurred during the June heatwave.

Both heatwaves shattered long-standing temperature records, with 35.1°C recorded in West London in May and 37°C in East Anglia in June.

"We are still in the first half of summer in the UK and large parts of England and Wales have already experienced two record-breaking heatwaves," said Dr Malcolm Mistry, Assistant Professor in Climate and Geo-spatial Modelling at LSHTM.

June 2026 Among The Hottest On Record

According to the Copernicus Climate Change Service (C3S), June 2026 was the hottest June ever recorded in western Europe and the second warmest globally.

The record temperatures were driven in part by the highest sea surface temperatures ever recorded for June.

"Heatwaves like this are what we expect to see in a changing climate," said John Kennedy, Head of Climate Information at the World Meteorological Organization (WMO).

He noted that Europe has warmed by around 2°C over the past 50 years, making it the world's fastest-warming continent and increasing the frequency of extreme heat events.

Why Extreme Heat Can Be Deadly

Extreme heat is often called the "silent killer" because heat-related deaths are frequently underreported. Globally, an estimated 489,000 people died from heat-related causes each year between 2000 and 2019, according to modeled estimates.

Heat stress develops when the body absorbs more heat than it can release. While sweating and increased blood flow to the skin normally help regulate body temperature, these cooling mechanisms become less effective during prolonged periods of intense heat—especially when humidity is high.

According to Lachlan McIver, Health Advisor at the WHO-WMO Climate and Health Joint Office, older adults, infants, pregnant women, outdoor workers, people experiencing homelessness, and those with chronic illnesses are at the greatest risk, although prolonged extreme heat can affect anyone.

In a breakthrough that could transform tuberculosis treatment (TB) in rural India, researchers from the Indian Council of Medical Research (ICMR) have demonstrated that drones can dramatically speed up the transport of TB samples, helping patients receive a diagnosis faster and significantly reducing the cost of treatment.

ICMR Uses Drones To Transport Patient Samples

Published recently in the International Journal of Tuberculosis and Lung Disease Open, the ICMR’s i-DRONE initiative is a pilot project conducted in Telangana’s Yadadri-Bhuvanagiri district.

The study is based on whether drones could transport sputum samples from remote health centres to TB diagnostic laboratories more efficiently than conventional road transport.

Researchers found that the turnaround time for TB diagnosis fell drastically from 15 days to just five days after drones were used to transport patients' sputum. The average time taken for diagnosis also dropped from 16.6 days to 6.9 days, helping patients seek TB treatment and care much earlier, which is a crucial factor in preventing disease progression and containing transmission.

The savings came primarily from eliminating repeated trips to distant diagnostic centres, reducing travel costs, wage losses, and other indirect expenses that often discourage people from seeking timely care.

The savings in patients’ costs primarily came from avoiding multiple trips to the diagnostic centres, wage losses, low travel costs, and other indirect expenses that often discourage patients from seeking timely care.

Also read: What Was The Pseudo-Tuberculosis Like 'Syndrome K' Saved Thousand Lives During World War II?

How Was The Study Conducted?

The year-long study is based on 840 patients, including 206 before the drone programme and 634 after its implementation. Instead of relying on road transport, healthcare workers collected sputum samples at the health facilities located in villages.

Drones then flew the samples directly to district TB laboratories, avoiding delays due to poor roads, difficult terrain, and limited public transport availability.

“The intervention demonstrated a significant reduction in the turnaround time and improved access to TB diagnosis in rural and remote Indian settings,” the researchers wrote.

The study also found that the speed of reporting improved substantially. Before drones were used, more than 90% of patients waited longer than two days to receive their test results. After the intervention, most patients received their reports within a day, allowing TB treatment to begin much sooner.

Bridging The Gap In Accessibility

Apart from faster diagnosis and low costs, researchers believe this technology could help overcome one of the biggest barriers to TB care - accessibility.

In several remote regions, patients often delay getting tested as travelling to district and city hospitals means losing a day’s wages, paying for transport, or arranging a family member to accompany them.

Drone transport takes away a significant part of that burden from patients. Healthcare workers who were interviewed during the project were also optimistic about using drone services and technology for other diseases beyond tuberculosis.

According to a companion feasibility study, many believed the same network and technology could eventually help transport blood samples, vaccines, medicines, and diagnostic specimens for other time-sensitive diseases.